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Objective To determine if change in maternal angiogenic

biomarkers between the first and second trimesters predicts
pre-eclampsia in low-risk nulliparous women.
Design A nested case–control study of change in maternal plasma
soluble Flt-1 (sFlt-1), soluble endoglin (sEng) and placenta growth
factor (PlGF). We studied 158 pregnancies complicated by preeclampsia and 468 normotensive nonproteinuric controls.
Setting A multicentre study in 16 academic medical centres in the USA.
Population Low-risk nulliparous women.
Methods Luminex assays for PlGF, sFlt-1 and sEng performed on
maternal EDTA plasma collected at 9–12, 15–18 and 23–26 weeks
of gestation. Rate of change of analyte between first and either
early or late second trimester was calculated with and without
adjustment for baseline clinical characteristics.
Main outcome measures Change in PlGF, sFlt-1 and sEng.

in women who developed pre-eclampsia, severe pre-eclampsia or
early-onset pre-eclampsia compared with women who remained
normotensive. Inclusion of clinical characteristics (race, body mass
index and blood pressure at entry) increased sensitivity for detecting
severe and particularly early-onset pre-eclampsia but not preeclampsia overall. Receiver operating characteristics curves for
change from first to early second trimester in sEng, PlGF and sFlt-1
with clinical characteristics had areas under the curve of 0.88, 0.84
and 0.86, respectively, and for early-onset pre-eclampsia with
sensitivities of 88% (95% CI 64–99), 77% (95% CI 50–93) and 77%
(95% CI 50–93) for 80% specificity, respectively. Similar results were
seen in the change from first to late second trimester.
Conclusion Change in angiogenic biomarkers between first and early

second trimester combined with clinical characteristics has strong
utility for predicting early-onset pre-eclampsia.
Keywords Angiogenesis, endoglin, platelet growth factor, preeclampsia, sFlt-1.

Results Rates of change of PlGF, sEng and sFlt-1 between first
and either early or late second trimesters were significantly different
Please cite this paper as: Myatt L, Clifton R, Roberts J, Spong C, Wapner R, Thorp J Jr, Mercer B, Peaceman A, Ramin S, Carpenter M, Sciscione A, Tolosa J, Saade
G, Sorokin Y, Anderson G. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in
a low-risk nulliparous patient population? BJOG 2013;120:1183–1191.
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Introduction
Pre-eclampsia, a leading cause of fetal growth restriction,
indicated premature delivery and maternal death, affects up
to 7% of pregnancies in the USA and is responsible for over
50 000 maternal deaths annually worldwide.1,2 There is
currently major interest in developing biomarkers to predict,
early in gestation, those women who will develop preeclampsia, particularly early-onset or severe pre-eclampsia.
Pre-eclampsia is described as a two-stage phenomenon
with abnormal placentation or uteroplacental perfusion
leading to increased inflammatory response and endothelial
dysfunction giving the systemic maternal syndrome.3 Proposed biomarkers for predicting onset or severity have been
those that measure trophoblast invasion, impedance to
uteroplacental blood flow, placental function, or production
of pro-angiogenic and anti-angiogenic factors. In crosssectional studies of women with established pre-eclampsia,
clear differences have been seen in levels of pro-angiogenic
and anti-angiogenic biomarkers.4,5 Although a high degree of
sensitivity and specificity for prediction of pre-eclampsia is
claimed for first-trimester measurement of biomarkers,6–8
our study in a low-risk nulliparous population9 and a recent
systematic review of 37 studies assessing 71 different
combinations of biochemical and ultrasonographic markers10 suggest that current first-trimester biomarkers may not
have sufficient sensitivity to be clinically useful. Crosssectional studies of biomarkers in late gestation show more
distinct differences between normotensive women and those
who will develop pre-eclampsia. Therefore, measuring
changes in biomarkers between the first and second trimesters has been proposed as a better early predictor than single
first-trimester values.11
The study objective was to test the hypothesis that
measurement of change in angiogenic biomarker levels
between the first and early or late second trimesters has
clinical utility in predicting pre-eclampsia. Although preeclampsia occurs at a higher rate in women with pre-existing
risk factors,12 this study used low-risk nulliparous women.

Methods
Study design
The Maternal Fetal Medicine Units network of the Eunice
Kennedy Shriver National Institute of Child Health and
Human Development conducted this study as a planned
observational cohort of a larger randomised controlled trial
to determine whether antioxidant supplementation
(1000 mg vitamin C and 400 iu vitamin E) prevents preeclampsia in nulliparous women at low risk for developing
the syndrome. Full details of the trial have been reported
previously.13 Women were eligible to participate in this
cohort if they were enrolled in the trial and their gestational
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age at enrolment was between 9 weeks 0 days and 12 weeks
6 days. Exclusion criteria were: a previous pregnancy lasting
beyond 19 weeks 6 days, an elevated blood pressure (systolic
pressure  135 mmHg or diastolic blood pressure
 85 mmHg), proteinuria (24-hour urine collection of
 300 mg protein or a dipstick value more than trace),
current use of antihypertensive medication, pre-gestational
diabetes, regular use or use within 7 days of platelet active
drugs or nonsteroidal anti-inflammatory agents, known fetal
abnormalities or demise, and a history of medical complications. Clinical information including demographic, medical, obstetric, social and sexual history was obtained at the
time of enrolment by patient interview and chart review.
Blood pressure, weight and urine protein concentrations
were recorded at monthly study visits. Blood was collected
into EDTA tubes at 9–12, 15–18 and 23–26 weeks of
gestation, plasma separated, divided into aliquots and stored
at – 70°C until analysis. A nested case–control study was
performed with approximately a 3:1 random sample of
normotensive, nonproteinuric women to women with preeclampsia, matched by centre and gestational age at enrolment.

Biochemical assays
We measured platelet growth factor (PlGF), a vascular
endothelial growth factor (VEGF) family member involved in
angiogenesis, sFlt, the soluble form of Flt-1 VEGF receptor,
and soluble endoglin (sEng), a transforming growth factor-b
co-receptor in EDTA plasma. Details of their assay have been
reported previously.9 The biomarkers were measured using
Luminex assays developed by Rules Based Medicine (Austin,
TX, USA). The inter-assay coefficients of variation were 9%
at 1.378 ng/ml for sFlt-1, 8% at 3.91 ng/ml for sEng, and
10% at 476 pg/ml for PlGF.

Definitions and outcomes
The primary outcome was the development of pre-eclampsia.
Secondary outcomes included the severity and gestational age
of pre-eclampsia onset. Mild pre-eclampsia was defined as
mild pregnancy-associated hypertension (140–159 mmHg
systolic or 90–109 mmHg diastolic on two occasions, 2–
240 hours apart) and proteinuria (300–4999 mg total protein/24 hours, 2+ or higher on dipstick testing, or a protein:
creatinine ratio of  0.35). Severe pre-eclampsia was defined
as pre-eclampsia with either severe pregnancy-associated
hypertension (  160 mmHg systolic or  110 mmHg diastolic on two occasions, 2–240 hours apart, or a single
occurrence treated with anti-hypertensives) or protein
excretion of 5 g or more in a 24-hour urine sample or as
mild pregnancy-associated hypertension with oliguria
(<500 ml), pulmonary oedema, or thrombocytopenia (platelet count of <100 000/mm3). Pre-eclampsia included mild
and severe pre-eclampsia, HELLP (haemolysis, elevated liver
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enzymes, low platelet count) syndrome and eclampsia. The
time of onset of pre-eclampsia (early onset defined as
<34 weeks or late onset defined as  34 weeks of gestation)
was determined as the time at which individuals first met the
criteria for diagnosis of pre-eclampsia given above.
Pre-eclampsia was confirmed via central review, using a
standardised protocol by three reviewers not associated with
the clinical site of origin, of de-identified medical records of
all women with pregnancy-associated hypertension.9

Table 1. Population characteristics
Characteristic

Pre-eclampsia
(n = 158)

No pre-eclampsia P-value
(n = 468)

Results

Gestational age at
Enrolment
(first-trimester)
15–18 weeks
of gestation
23–26 weeks
of gestation
Maternal age
(years)
Race
African American
Hispanic
Caucasian/other
Previous
pregnancy
(<20 weeks)
Family history
of pre-eclampsia
Smoked during
pregnancy
BMI at enrolment
Blood pressure
at enrolment
Systolic (mmHg)
Diastolic (mmHg)
Treatment group
Vitamins C and E
Placebo

Population characteristics

Data presented as n (%) or median (25–75th centile).

Statistical analysis
Categorical variables were compared using the chi-square test
and continuous variables using the Wilcoxon rank sum test.
The change in biomarker concentrations between the first
(9–12 weeks) and early second (15–18 weeks of gestation)
trimesters and between first and late second (23–26 weeks of
gestation) trimesters was calculated as rate of change = difference in concentration (pg/ml or ng/ml) divided by
number of weeks between measurements. The performance
of screening was determined with and without adjustment
for significant clinical factors by receiver operating characteristic curves and calculating the sensitivity for a fixed 80%
specificity.
Unless specifically noted, a nominal P value <0.05
indicated statistical significance and no adjustments were
made for multiple comparisons. Analyses were performed
using SAS software (SAS Inc., Cary, NC, USA).

A total of 626 women, 158 diagnosed with pre-eclampsia and
468 normotensive, non-proteinuric, had biomarkers available in both the first trimester and early second trimester. Of
these, five delivered before 23 weeks of gestation and 109 did
not have a late second trimester blood collection, such that
137 women with pre-eclampsia and 375 normotensive
control women were available and used in comparisons of
first and late second trimester values. The population
characteristics for all women included in the analysis are
reported in Table 1. The median gestational age at enrolment
was 11.4 weeks (pre-eclampsia) and 11.6 weeks (normotensive controls). Overall there was a significant difference in
ethnicity between the women who developed pre-eclampsia
and those who remained normotensive. Although there was
no difference in the proportion of women who were
Hispanic between groups, more women were African American in the pre-eclampsia group with a corresponding
reduction in the proportion who were Caucasian. Of those
women in this analysis, 13.6% had a family history of preeclampsia, 16.8% were smokers and 20.9% had been
previously pregnant; there was no difference in these
incidences between those who developed pre-eclampsia and

sample collection (weeks)
11.4 (10.4–12.3) 11.6 (10.6–12.3)

0.62

16.6 (16.0–17.4)

16.4 (16.0–17.0)

0.06

24.7 (24.0–25.7)

24.7 (24.0–25.6)

0.54

22 (19–25)

22 (19–26)

0.88
0.019

51
49
58
34

(32.3)
(31.0)
(36.7)
(21.5)

103
145
220
97

(22.0)
(31.0)
(47.0)
(20.7)

0.83

21 (13.3)

64 (13.7)

0.90

26 (16.5)

79 (16.9)

0.90

26.7 (22.9–31.6)

23.5 (21.4–27.6)

<0.001

112 (108–120)
68 (60–72)

107 (100–115)
64 (60–70)

<0.001
<0.001
0.79

83 (52.5)
75 (47.5)

240 (51.3)
228 (48.7)

those who remained normotensive. However, median body
mass index (BMI) and systolic and diastolic blood pressures
were significantly greater at enrolment in those women who
subsequently developed pre-eclampsia. Patients were equally
randomised to vitamins or antioxidants in the clinical trial.
The overall incidence of pre-eclampsia among women in this
trial was 7.6% and was not different between those who did
or did not receive antioxidants.

Angiogenic markers
There was no effect of supplementation with vitamins on the
concentrations of angiogenic factors. In women who
remained normotensive maternal concentrations of both
sFlt-1 and PlGF increased from first to early second trimester
and from first to to late second trimester (as evidenced by the
rate of change, Tables 2 and 3) whereas the concentration of
sEng declined slightly over this time. The rates of the change in
the biomarkers between first and early second trimesters were
significantly different for sEng and PlGF, but not for sFlt-1,
between those individuals who developed pre-eclampsia and
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Table 2. Rate of change in maternal plasma angiogenic factors from first to early second trimester (15–18 weeks of gestation)

sFlt (pg/ml)
First trimester
Second trimester
(15–18 weeks)
Rate of change
(pg/ml/week)
Endoglin (ng/ml)
First trimester
Second trimester
(15–18 weeks)
Rate of change
(ng/ml/week)
PlGF (pg/ml)
First trimester
Second trimester
(15–18 weeks)
Rate of change
(pg/ml/week)

Normotensive
(n = 468)

Pre-eclampsia
(n = 158)

1290 (843–1785)
1530 (987–2355)

1140 (793–1740)
1340 (841–2170)

P*

Severe PE
(n = 64)

P**

Early-onset PE
(n = 17)

P***

0.14
0.07

1000 (762–1450)
1215 (819–2095)

0.007
0.08

958 (762–1680)
1490 (781–2200)

0.19
0.95

40 ( 33–148)

37 ( 21–133)

0.78

53 ( 16–136)

0.52

80 ( 6–143)

0.35

4.4 (3.7–5.4)
4.2 (3.4–5.2)

4.4 (3.6–5.5)
4.2 (3.5–5.3)

0.50
0.51

4.3 (3.6–5.2)
4.3 (3.5–5.9)

0.20
0.22

3.7 (3.5–4.8)
4.2 (3.4–6.3)

0.16
0.47

–0.06 (–0.23 to 0.09)

–0.02 (–0.15 to 0.15)

0.036

0.01 (–0.11–0.22)

0.004

0.09 (–0.08–0.38)

0.05

26.2 (18.6–37.6)
99.0 (69.7–140.0)

22.4 (14.8–31.7)
79.0 (53.1–121.0)

<0.001
<0.001

22.3 (15.7–27.9)
73.3 (51.9–112.5)

<0.001
0.002

26.0 (14.6–42.1)
85.5 (38.0–122.0)

0.49
0.07

13.8 (8.8–21.3)

10.8 (6.5–17.2)

<0.001

9.7 (5.9–17.3)

0.002

12.1 (3.0–18.9)

0.16

PE, pre-eclampsia.
Data presented as median (25–75th centile).
*Pre-eclampsia compared with normotensive.
**Severe preeclampsia compared with normotensive.
***Early onset preeclampsia compared with normotensive.

Table 3. Rate of change of maternal plasma angiogenic factors from first to late second trimester (23–26 weeks of gestation)

sFlt (pg/ml)
First trimester
Second trimester
(23–26 weeks)
Rate of change
(pg/ml/week)
Endoglin (ng/ml)
First trimester
Second trimester
(23–26 weeks)
Rate of change
(ng/ml/week)
PlGF (pg/ml)
First trimester
Second trimester
(23–26 weeks)
Rate of change
(pg/ml/week)

Normotensive
(n = 375)

Pre-eclampsia
(n = 137)

P*

Severe PE
(n = 54)

P**

1290 (840–1820)
1480 (967–2360)

1110 (762–1680)
1570 (924–2570)

0.038
0.59

943 (741–1430)
1620 (924–3220)

16.4 (–17.9–60.6)

23.1 (–7.9–81.0)

0.044

4.4 (3.6–5.5)
4.3 (3.7–5.5)

0.81
0.34

0.007 ( 0.09–0.05)

0.004 (–0.08–0.06)

0.20

0.032 ( 0.03–0.09)

0.002

27.4 (18.6–38.4)
360 (252–558)

22.4 (14.8–31.7)
240 (151–398)

<0.001
<0.001

22.0 (15.5–27.6)
210 (133–366)

25.6 (16.7–40.4)

16.8 (9.5–26.6)

<0.001

13.8 (8.9–24.5)

4.4 (3.7–5.3)
4.2 (3.6–5.2)

Early-onset PE
(n = 15)

P***

0.001
0.39

949 (625–1450)
1570 (924–4350)

0.038
0.52

43.0 (7.9–100.1)

<0.001

20.6 (1.6–249.2)

0.09

4.3 (3.6–5.2)
4.9 (3.9–6.0)

0.52
0.013

3.7 (3.5–4.8)
4.9 (3.4–7.2)

0.15
0.33

0.02 ( 0.02–0.18)

0.06

<0.001
<0.001

26.0 (14.6–45.1)
169 (85–366)

0.63
0.002

<0.001

9.5 (4.8–25.6)

0.003

PE, pre-eclampsia.
Data presented as median (25–75th centile).
*Pre-eclampsia compared with normotensive.
**Severe pre-eclampsia compared with normotensive.
***Early onset pre-eclampsia compared with normotensive.
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those who remained normotensive (Table 2). When the
different clinical phenotypes of pre-eclampsia were considered
the rates of change in sEng and PlGF were again significantly
less in those who developed severe pre-eclampsia compared
with those who remained normotensive (Table 2). However,
the rate of change for sEng between first and early second
trimesters almost reached significance and that for sFlt and
PlGF was not significantly different for those who developed
early onset pre-eclampsia compared with women who
remained normotensive (Table 2). When receiver operating
characteristic curves were constructed for the change in
biomarkers, the greatest areas under the curve (AUC) were for
sEng (0.61, 95% CI 0.54–0.68) and for PlGF (0.62, 95% CI
0.54–0.70) for those women who developed severe preeclampsia (Figure 1A) and 0.64 (95% CI 0.49–0.79) and 0.60
(95% CI 0.43–0.77), respectively, for those who developed
early onset pre-eclampsia (Figure 1B). The sensitivity of PlGF
for predicting early onset pre-eclampsia was 47% (95% CI 23–
72) at an 80% specificity but only 41% (95% CI 29–54) for
prediction of severe pre-eclampsia. When data for change
between first trimester and late second trimester were
considered, the rate of change for PlGF (reduced), sFlt-1 but
not sEng was significantly different in women who developed
pre-eclampsia compared with women who remained normotensive (Table 3). The rate of change for all three analytes was
significantly different in women who developed severe preeclampsia compared with women who remained normotensive. Only the rate of change of PlGF was significantly different
comparing those who developed early onset pre-eclampsia
with those who remained normotensive (Table 3).
The predictive performance was reanalysed following
addition of the clinical characteristics, race, BMI and blood
pressure at enrolment. For changes from first to early second
trimester (Table 4) each analyte still only yielded an AUC
<0.70 and a sensitivity <45% at 80% specificity for predicting
pre-eclampsia (Figure 1C, D, Table 4). However, for prediction of early onset pre-eclampsia the AUC for sEng was 0.88
(95% CI 0.83–0.93) yielding a sensitivity of 88.2% (95% CI
63.6–98.5) at 80% specificity, with performance of sFlt-1 and
PlGF only slightly less (Figure 1E, Table 4). The performance
for predicting severe pre-eclampsia (Figure 1F, Table 4) was
better than that of the biomarkers alone (Figure 1B) but did
not match that for prediction of early-onset pre-eclampsia.
Similar results were seen for the change from first to late
second trimester (Table 5). The sensitivity of PlGF for severe
pre-eclampsia reached 60% and the sensitivity of sFlt for
prediction of early onset pre-eclampsia now reached 80%.

Discussion
In this study examining rates of change in pro-angiogenic
and anti-angiogenic markers alone from the first to early
second trimester in the low-risk nulliparous population, we

find no better sensitivity for predicting pre-eclampsia than
our previous analysis of first-trimester markers alone, as
ratios or in combination with clinical indices (AUC 0.73 and
sensitivity 46% at 20% false-positive rate).9 However, the
combination of change in biomarkers with the baseline
clinical characteristics of race, BMI and blood pressure
increased predictive performance. While performance for
pre-eclampsia and severe pre-eclampsia still only reached the
levels reported previously using first-trimester biochemical
and clinical indices,9 an AUC of 0.88 and sensitivity of 88%
for early-onset pre-eclampsia was achieved for change in
soluble endoglin between first trimester (median 11 weeks)
and early second trimester (15–18 weeks). Measuring change
between first and late second trimester with clinical characteristics yielded a slightly lower AUC and sensitivity for
detecting early-onset pre-eclampsia with sEng but the
performance of all three angiogenic factors for detection of
severe pre-eclampsia improved somewhat with PlGF giving
an AUC of 0.74 and sensitivity of 59%.
This study is unique as a prospectively designed longitudinal study in a population at low risk for developing preeclampsia enrolled in the first trimester. All material was
collected and biophysical measurements were performed in a
standardised manner by personnel trained in the methodology. Pre-eclampsia was defined according to pre-established
criteria and independently reviewed by a panel of three
individuals blinded to patient identity. The women were part
of a randomised trial of antioxidants.13 We focused on
nulliparous women because this group accounts for most
cases of pre-eclampsia in clinical practice. We performed by
far the largest, comprehensive longitudinal study of trophoblast and angiogenic markers.
Placental growth factor shares homology with VEGF,
which can induce proliferation, migration and activation of
endothelial cells,14 but which is expressed in villous cytotrophoblast, syncytiotrophoblast and extravillous trophoblast.15,16 Women who subsequently develop pre-eclampsia
show reduced PlGF concentrations even in the first trimester
and the difference between these women and those who
remain normotensive becomes more marked as pregnancy
progresses.17 Of the angiogenic factors we have measured in
the first trimester, PlGF has the best predictive power but has
a low sensitivity.9 Maternal blood concentrations of the antiangiogenic factors sFlt-1 and sEng, both also produced by
trophoblast,18 are low throughout the first and second
trimesters and only increase markedly in the third trimester.
Previously Vatten et al.19 using a retrospective nested case–
control study of women of all parities and Kusanovic et al.20
using a longitudinal cohort approach performed similar
studies for PlGF, VEGF, sFlt-1 and sEng reporting that
change in concentration of PlGF from first to either early or
late second trimester was the best predictor, being significantly different both for all pre-eclampsia and for any of the
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(A)

(B)

(C)

(D)

(E)

(F)

Figure 1. Receiver operating characteristic curves for rate of change in concentration of biomarkers between first and early second trimester for (A) earlyonset pre-eclampsia and (B) severe pre-eclampsia, and with the addition of race, body mass index and blood pressure between (C) first and early second
trimester for pre-eclampsia, (D) first and late second trimester for pre-eclampsia, (E) first and early second trimester for early-onset pre-eclampsia or (F) first
and early second trimester for severe pre-eclampsia.

four clinical phenoytypes, mild, severe, early onset or late
onset from women who remained normotensive. We find
that the rate of change of PlGF was significantly different for
all three phenotypes examined, except for early-onset preeclampsia, using data from first to early second trimester.
The small number (n = 17) of women with early onset
(<34 weeks of gestation) potentially limited the predictive
power of our analysis for this subtype, although we have

1188

more cases than Kusanovic et al.20 at <34 weeks (n = 9) and
Vatten et al.19 only studied <37 weeks of gestation. In
contrast to PlGF, the rate of change from first to early
second trimester for sEng was significantly different for all
pre-eclampsia and severe pre-eclampsia, but that for sFlt-1
was not related to any subtype. When examining change
from first to late second trimester, sEng is only significant for
severe pre-eclampsia and sFlt-1 for all pre-eclampsia and
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Table 4. Area under the curve from receiver operating curves and sensitivity at a fixed 80% specificity for changes in biomarker concentrations
adjusted for race, BMI and blood pressure between first and early second trimesters with severe or early-onset pre-eclampsia
Biomarker
(rate of
change)
sFlt
Endoglin
PlGF

Pre-eclampsia (n = 158)

Severe pre-eclampsia (n =64)

Early Onset pre-eclampsia (n = 17)

AUC (95% CI)

Sensitivity (95% CI)

AUC (95% CI)

Sensitivity (95% CI)

AUC (95% CI)

Sensitivity (95% CI)

0.69 (0.64–0.74)
0.69 (0.65–0.74)
0.69 (0.64–0.74)

44.3 (36.4–52.4)
43.7 (35.8–51.8)
42.4 (34.6–50.5)

0.68 (0.61–0.74)
0.70 (0.64–0.77)
0.68 (0.61–0.75)

34.4 (22.9–47.3)
40.6 (28.5–53.6)
39.1 (27.1–52.1)

0.86 (0.79–0.92)
0.88 (0.83–0.93)
0.84 (0.76–0.93)

76.5 (50.1–93.2)
88.2 (63.6–98.5)
76.5 (50.1–93.2)

Table 5. Area under the curve from receiver operating curves and sensitivity at a fixed 80% specificity for changes in biomarker concentrations
adjusted for race, BMI and blood pressure between first and late second trimesters with severe or early-onset pre-eclampsia
Biomarker
(rate of
change)
sFlt
Endoglin
PlGF

Pre-eclampsia (n = 137)

Severe pre-eclampsia (n = 54)

Early-onset pre-eclampsia (n = 15)

AUC (95% CI)

Sensitivity (95% CI)

AUC (95% CI)

Sensitivity (95% CI)

AUC (95% CI)

Sensitivity (95% CI)

0.71 (0.66–0.76)
0.71 (0.66–0.76)
0.70 (0.65–0.76)

47.4 (38.9–56.1)
51.1 (42.4–59.7)
48.2 (39.6–56.9)

0.73 (0.65–0.80)
0.72 (0.65–0.80)
0.73 (0.65–0.81)

57.4 (43.2–70.8)
46.3 (32.6–60.4)
59.3 (45.0–72.4)

0.88 (0.81–0.95)
0.87 (0.81–0.94)
0.85 (0.76–0.93)

80.0 (51.9–95.7)
73.3 (44.9–92.2)
73.3 (44.9–92.2)

severe pre-eclampsia. The sensitivity of such change for
severe pre-eclampsia reached 60% for PlGF from first to
late second trimester at a fixed 80% specificity. For earlyonset pre-eclampsia the sensitivity was better, reaching 73–
77% for early and late second time intervals. Earlier studies
had also shown that a combination of the slopes of PlGF and
sEng gave the best predictive value particularly for earlyonset pre-eclampsia.19,20 Indeed the study by Kusanovic
et al.20 claimed a sensitivity of 100% with a specificity of 98–
99% for prediction of early-onset pre-eclampsia using the
PlGF:sEng ratio. Determining the slopes of the PlGF:sFlt or
PlGF:sEng ratios did not improve sensitivity above that of
PlGF alone (data not shown).

Conclusion
In contrast to previous reports we do not find that
assessment of changes in angiogenic markers alone from
first to second trimester can improve predictive power.
However, addition of baseline clinical characteristics
improved the predictive power for severe and particularly
for early-onset pre-eclampsia such that sensitivity reached
88% at an 80% specificity. This differential sensitivity for
detection of early-onset pre-eclampsia reinforces the idea
that the there may be more than one pathophysiological
phenotype.21 As the utility of therapeutic intervention to
change the pathological course or of surveillance would be
enhanced by prediction as early as possible in gestation,
measurement of change between first trimester (median

11 weeks) and early second trimester (15–18 weeks) appears
to have the most value, particularly as the test has highest
sensitivity for early-onset pre-eclampsia, the group with
shortest time available for intervention. Future studies
should focus on the utility of combinations of biomarkers
and clinical factors in prediction of different clinical phenotypes of pre-eclampsia.
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